艾地苯醌治疗脑卒中后患者认知障碍的临床效果

Clinical Effect of Adebenquinone in the Treatment of Cognitive Impairment after Stroke

目的探究脑卒中后患者认知障碍应用艾地苯醌进行治疗的临床效果。方法此次试验对象选择本院2017年3月至2019年8月期间收治的120例脑卒中存在认知障碍的患者,随机分成试验组(n=60)和对照组(n=60),对照组患者进行基础康复治疗,试验组在此基础上选择艾地苯醌治疗,对比两种治疗方案对患者产生的影响。结果治疗前,两组在MoCA评分、MMSE评分上相比,差异无统计学意义(P>0.05);治疗后,两组MoCA评分、MMSE评分对比,差异有统计学意义(P<0.05)。试验组的住院时间和对照组相比,差异有统计学意义(P<0.05);试验组的治疗总有效率为95.00%,和对照组的83.33%相比,差异有统计学意义(P<0.05);两组患者的不良反应发生率对比,差异无统计学意义(P>0.05)。结论脑卒中后认知障碍患者应用艾地苯醌进行治疗的临床效果显著,可有效改善患者的认知障碍,缩短住院时间,加速康复速度,且治疗安全性较高。

Objective To explore the clinical effect of aldibenzoquinone in the treatment of cognitive impairment after stroke.Methods A total of 120 patients with cognitive impairment after stroke admitted to our hospital from March 2017 to August 2019 were randomly divided into experimental group(n=60)and control group(n=60).The patients in control group were given basic rehabilitation treatment.On this basis,the experimental group was treated with adebenquinone,and the effects of the two treatment schemes on patients were compared.Results On the MoCA score and MMSE score,there was no significant difference between the experimental group and the control group before treatment(P>0.05).There was significant difference between the two groups after treatment(P<0.05).The difference between the hospital stay and the control group in the experimental group was statistically significant(P<0.05).The total effective rate of the experimental group was 95.00%,which was statistically significant compared with the control group(83.33%)(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The The clinical effect of treatment with idebenone in patients with post-stroke cognitive impairment is significant,which caneffective improve cognitive impairment,shorten hospital stay,accelerate recovery,and have higher treatment safety.